Hubro Therapeutics

Is a privately held biopharmaceutical company devoted to the development and commercialization of novel proprietary therapeutic and prophylactic cancer vaccines.

Company highlights

  • Hubro’s proprietary peptide vaccines target tumour specific antigens resulting from microsatellite instability and frameshift mutation
  • Our single- and multi-target vaccines demonstrate both therapeutic and prophylactic potential
  • We are exploring technology for detection of frameshift mutations in liquid biopsies
  • Hubro has a strong focus on intellectual property rights
  • Hubro Therapeutics’ research is supported by the Norwegian Research Council

Hubro is the Norwegian name for the Eurasian eagle owl – known for its extremely sharp night vision and its ability to see what most others cannot. In our research, we find that ability inspiring.”

– Jon Amund Eriksen, CEO Hubro Therapeutics

Immunotherapy market

The global cancer immunotherapy market was valued at $57,256.2 million in 2017 and is expected to reach $166,714.5 million by 2025, registering a CAGR of 14.42% during the period, 2018-2025 [1].

The lead candidate FMPV-1 is a neoantigen peptide vaccine which will enter clinical phase in the fourth quarter of 2021. The target is frameshift mutations greatly associated with colorectal cancer including hereditary disease and gastric cancer.

Hollingsworth, R. E. & Jansen, K. NPJ vaccines 4, 7, doi:10.1038/s41541-019-0103-y (2019).

Experienced team

The Company has a highly experienced international management and operational team, an extensive network of industrial and academic partners to optimise and leverage the development of its novel technology.

The CEO Jon Amund Eriksen has established multiple successful cancer immunology companies and is a highly respected individual in the field of peptide vaccines.

Chairman of the Board is Jonas Einársson, CEO of Radforsk – one of the leading cancer incubators globally, with an extensive track record of commercializing cancer research.

This website uses cookies to ensure you get the best experience on our website.